Lys24
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys24  -  AML1 (human)

Site Information
stALsPGkMSEALPL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 459071
Available spectra:  5 CST

In vivo Characterization
Methods used to characterize site in vivo:
3H acetate labeling ( 18 ) , [14C] acetate labeling ( 18 ) , immunoprecipitation ( 18 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 ) , mutation of modification site ( 18 ) , western blotting ( 18 )
Disease tissue studied:
gastric cancer ( 10 ) , leukemia ( 16 , 18 ) , T cell leukemia ( 18 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 2 , 3 , 4 , 5 , 6 , 8 , 9 , 11 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 4 , 5 , 9 ) , non-small cell large cell lung carcinoma ( 2 , 5 ) , non-small cell squamous cell lung carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
vorinostat ( 13 )

Downstream Regulation
Effects of modification on AML1:
molecular association, regulation ( 18 )
Effects of modification on biological processes:
cell growth, induced ( 18 ) , transcription, induced ( 18 )
Induce interaction with:
DNA ( 18 )

References 

1

Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

8

Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

9

Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

10

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

11

Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

12

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

13

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

14

Cherry J (2007) CST Curation Set: 2475; Year: 2007; Biosample/Treatment: cell line, MV4-11/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

15

Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

16

Gu T (2005) CST Curation Set: 1005; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

17

Gu T (2005) CST Curation Set: 957; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

18

Yamaguchi Y, et al. (2004) AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 279, 15630-8
14752096   Curated Info